| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/06/2013 | EP2564851A2 Agent exhibiting the properties of a cognitive function promoter (embodiments) |
| 03/06/2013 | EP2564850A1 Polo-like kinase inhibitors |
| 03/06/2013 | EP2564849A1 Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
| 03/06/2013 | EP2564848A1 Transdermally absorbable donepezil-containing preparation |
| 03/06/2013 | EP2564847A1 Pharmaceutical composition for improving solubility of prasugrel and its preparation method |
| 03/06/2013 | EP2564846A1 Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with anti-cd20 agents |
| 03/06/2013 | EP2564845A1 Diindolylmethane-based drug for the treatment of hyperplastic and inflammatory diseases |
| 03/06/2013 | EP2564844A2 Composition for treating bone disease comprising a glyceollin as an active ingredient |
| 03/06/2013 | EP2564843A1 Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| 03/06/2013 | EP2564842A1 Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| 03/06/2013 | EP2564841A1 Use of travoprost for treating hair loss |
| 03/06/2013 | EP2564840A1 Compositions for the symptomatic relief of stomach pain or gastro-oesophageal reflux |
| 03/06/2013 | EP2564839A2 Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| 03/06/2013 | EP2564838A1 Enteric tablet |
| 03/06/2013 | EP2564837A1 Enteric tablet |
| 03/06/2013 | EP2564835A1 Fast-dissolving solid pharmaceutical form for treating bacterial infections |
| 03/06/2013 | EP2564834A2 Compounds for Proteasome Enzyme Inhibition |
| 03/06/2013 | EP2564833A1 Photostabilized pharmaceutical composition |
| 03/06/2013 | EP2564832A1 Solid dosage form of HIV protease inhibitors |
| 03/06/2013 | EP2563923A2 Compositions and methods for reduced scarring and for treatment of fibrosis |
| 03/06/2013 | EP2563804A2 Preparation of polypeptides and salts thereof |
| 03/06/2013 | EP2563803A1 Anticancer steroidal lactones unsaturated in position 7 (8) |
| 03/06/2013 | EP2563801A2 Substitution derivatives of n6-benzyladenosine-5´-monophosphate, methods of preparation thereof, use thereof as medicaments, and therapeutic preparation containing these compounds |
| 03/06/2013 | EP2563796A1 Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs |
| 03/06/2013 | EP2563795A1 Inhibitors of protein tyrosine kinase activity |
| 03/06/2013 | EP2563794A1 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders |
| 03/06/2013 | EP2563792A1 Imidazopyridazinyl compounds and their uses for cancer |
| 03/06/2013 | EP2563789A1 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors |
| 03/06/2013 | EP2563788A1 Naphthridine derivatives as pi3k inhibitors for the treatment of cancer and immune - inflammatory diseases |
| 03/06/2013 | EP2563787A1 Azaindazole amide compounds as ccr1 receptor antagonists |
| 03/06/2013 | EP2563785A1 Compounds as agonists of s1p1 receptors |
| 03/06/2013 | EP2563783A1 3-(4-((1h-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators |
| 03/06/2013 | EP2563782A1 Polymorphs of a metabotropic glutamate receptor positive allosteric modulator |
| 03/06/2013 | EP2563780A1 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1]oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl]methanones as inhibitors of 11 (beta) -hsd1 |
| 03/06/2013 | EP2563778A1 Solid forms of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide |
| 03/06/2013 | EP2563777A2 Inverse agonists and neutral antagonists for the tsh receptor |
| 03/06/2013 | EP2563776A2 Compounds that modulate intracellular calcium |
| 03/06/2013 | EP2563775A1 Pyrazolyl quinazoline kinase inhibitors |
| 03/06/2013 | EP2563774A1 Pyrimidinyl indole compounds |
| 03/06/2013 | EP2563773A1 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
| 03/06/2013 | EP2563771A2 Metalloenzyme inhibitor compounds |
| 03/06/2013 | EP2563769A1 Diyne compositions |
| 03/06/2013 | EP2563768A2 Preparation of febuxostat |
| 03/06/2013 | EP2563766A1 Improved process for preparing rufinamide intermediate |
| 03/06/2013 | EP2563765A1 Bicyclic compound derivatives and their use as acc inhibitors. |
| 03/06/2013 | EP2563763A1 Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide |
| 03/06/2013 | EP2563761A1 Activators of human pyruvate kinase |
| 03/06/2013 | EP2563759A2 Compounds that modulate intracellular calcium |
| 03/06/2013 | EP2563758A1 New compounds, synthesis and use thereof in the treatment of pain |
| 03/06/2013 | EP2563477A1 Methods and compositions for inducing satiety |
| 03/06/2013 | EP2563406A1 Methods, compositions, and kits for the treatment of matrix mineralization disorders |
| 03/06/2013 | EP2563391A1 Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
| 03/06/2013 | EP2563384A2 Immunogenic compositions and methods for treating neoplasia |
| 03/06/2013 | EP2563379A1 Sox9 inhibitors |
| 03/06/2013 | EP2563376A1 Dermatological composition based on argan oil and hyaluronic acid |
| 03/06/2013 | EP2563374A1 Polyethylene glycol compositions for controlling relapse of herpes labialis, herpes genitalis, and herpes zoster |
| 03/06/2013 | EP2563373A1 Amorphous roxithromycin composition |
| 03/06/2013 | EP2563372A1 Prebiotic formulations and methods of use |
| 03/06/2013 | EP2563371A1 Anti-bacterial applications of poly -n-acetylglucosamine nanofibers |
| 03/06/2013 | EP2563370A1 Use of a composition containing phospholipids and glycyrrhizinic acid for removing subcutaneous fat accumulations by means of subcutaneous lipolysis |
| 03/06/2013 | EP2563369A2 Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof |
| 03/06/2013 | EP2563368A1 Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferative disorders |
| 03/06/2013 | EP2563367A1 Methods of treating retroviral infections and related dosage regimes |
| 03/06/2013 | EP2563366A2 Uses of phospholipid conjugates of synthetic tlr7 agonists |
| 03/06/2013 | EP2563365A1 Certain amino-pyridazines, compositions thereof, and methods of their use |
| 03/06/2013 | EP2563364A1 Combination of carmoterol and fluticasone for use in the treatment respiratory diseases |
| 03/06/2013 | EP2563363A2 Nmn modulator |
| 03/06/2013 | EP2563362A1 Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites |
| 03/06/2013 | EP2563361A1 Boosting immune defense by upregulating ccaat/enhancer binding protein epsilon |
| 03/06/2013 | EP2563360A2 Biomarkers for mdm2 inhibitors for use in treating disease |
| 03/06/2013 | EP2563359A1 Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| 03/06/2013 | EP2563358A1 Inhibitors of phosphoinositide dependent kinase 1 (pdk1) |
| 03/06/2013 | EP2563357A1 Method for treating scars with adapalene 0.3% |
| 03/06/2013 | EP2563356A2 A composition for skin sanitization and protection and method of its use |
| 03/06/2013 | EP2563355A1 Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers |
| 03/06/2013 | EP2563354A1 Metal entrapped bioactive composites |
| 03/06/2013 | EP2563353A2 Compounds for anti-fungal treatment |
| 03/06/2013 | EP2563352A1 Formulations of quinones for the treatment of ophthalmic diseases |
| 03/06/2013 | EP2563351A1 Adhesive slow-release formulations for the local administration of curcumin |
| 03/06/2013 | EP2563350A2 Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency |
| 03/06/2013 | EP2563349A1 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof |
| 03/06/2013 | EP2563348A1 New combination therapy in treatment of oncological and fibrotic diseases |
| 03/06/2013 | EP2563347A2 Propynylaminoindan transdermal compositions |
| 03/06/2013 | EP2563346A1 Solid oral dosage forms comprising tadalafil |
| 03/06/2013 | EP2563345A2 Layered drug delivery device |
| 03/06/2013 | EP2563344A1 Oral dosage forms |
| 03/06/2013 | EP2563341A1 Pharmaceutical compositions inducing synergistic effect |
| 03/06/2013 | EP2563340A2 Water soluble pharmaceutical composition |
| 03/06/2013 | EP2563339A1 Controlled release pharmaceutical compositions of brivaracetam |
| 03/06/2013 | EP2563337A1 Carrier and targeting system comprising a siosomal composition for intracellular delivery and targeting of active substance |
| 03/06/2013 | EP2563336A2 Aerosol foams comprising clindamycin phosphate |
| 03/06/2013 | EP2563335A2 Low-oil pharmaceutical emulsion compositions comprising progestogen |
| 03/06/2013 | EP2563334A2 Pharmaceutical emulsion compositions comprising progestogen |
| 03/06/2013 | EP2563331A2 Pharmaceutical powder compositions |
| 03/06/2013 | EP2563330A2 Nicotine-containing pharmaceutical compositions |
| 03/06/2013 | EP2563329A2 Orally disintegrating tablet containing acarbose |
| 03/06/2013 | EP2563167A1 Methods and lipid compositions for promoting development of gut flora |
| 03/06/2013 | EP2563166A1 Use of human milk oligosaccharides in infant nutrition |
| 03/06/2013 | EP2563165A1 Use of 6'-sialyl lactose in infant and toddler nutrition |
| 03/06/2013 | EP2563143A1 Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2 |